MedTrace Logo

Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)

NCT01834638 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 268

Last updated 2018-05-02

No results posted yet for this study

Summary

This is a study of ABT-126 in the treatment of cognitive impairment associated with schizophrenia (CIAS), a long-term extension study to study M10-855 (NCT01655680).

Conditions

Interventions

DRUG

ABT-126

capsule(s)

Sponsors & Collaborators

Principal Investigators

  • George Haig, PharmD · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
66 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • United States
  • Russia
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01834638 on ClinicalTrials.gov